Slate Medicines | $130,000,000 | (Feb 25, 2026)
Letter AI | $40,000,000 | (Feb 25, 2026)
Subject | $28,000,000 | (Feb 25, 2026)
Certified by Founder
Lodge
Maze Therapeutics
start up
United States
- South San Francisco, California
- 04/12/2024
- Series D
- $115,000,000
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.
- Industry Biotechnology Research
- Website https://mazetx.com/
- LinkedIn https://www.linkedin.com/company/mazetx/
![OSYTE [O-Sight]](/uploads/elmpLMcVgikenkl1732071438.png)
KrisAtWork | $3,000,000 | (Feb 25, 2026)
Centauri Therapeutics Limited | $8,107,170 | (Feb 25, 2026)
Slang AI | $36,000,000 | (Feb 25, 2026)
Brilliant Harvest Inc. | $4,000,000 | (Feb 25, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)
General Magic | $7,200,000 | (Feb 25, 2026)
Circadian Risk Inc. | $6,000,000 | (Feb 25, 2026)
Neural Earth | $9,300,000 | (Feb 25, 2026)
Jampack AI | $3,200,000 | (Feb 25, 2026)